According to the new market research report "Synthetic
Biology Market by Tool (Oligonucleotides, Chassis Organisms, Enzymes),
Technology (Genome Engineering, NGS, Cloning and Sequencing), Application
(Medical (Pharmaceutical, Drug Discovery), Industrial (Renewable Energy)) -
Global Forecast to 2022", published by MarketsandMarkets™, The global
synthetic biology market is expected to grow from USD 3.57 billion in 2017 to
USD 8.84 billion by 2022, at a CAGR of 19.9% from 2017 to 2022.
Synthetic biology has an array of applications in the fields
of medicine, agriculture, nanotechnology, and industrial biotechnology. This
has attracted interests of researchers from across the globe and has led to a
rise in funding from public and private organizations, which, in turn, help in
the growth of the market. Additionally, the reduction in costs per raw megabase
of DNA sequencing and a drastic reduction in the cost of synthetic genes is
expected to propel the market growth of synthetic biology. The base year
considered for the study is 2016, and the forecast has been provided for the
period between 2017 and 2022.
Wide range of
applications of synthetic biology drives the global synthetic biology market
The field of medicine has been in the forefront in terms of
developing and applying synthetic biology techniques for various applications.
Advancements in DNA sequencing and synthesizing technologies have resulted in
the better understanding of diseases, aiding the research and discovery of
biopharmaceuticals, small molecules, regenerative medicine, and antibody
research.
Browse and in-depth
TOC on "Synthetic Biology Market"
121 - Tables
32 - Figures
214 - Pages
Get Free 10%
customization:
The synthetic biology market comprises a network of players
involved in the research and product development; raw material supply;
component manufacturing; distribution and sale; and post-sales services. Key
players considered in the analysis of the global market are Thermo Fisher (US),
Novozymes (Denmark), Merck KGaA (Germany), Intrexon (US), and Agilent
Technologies (US), Amyris (US), GenScript (US), Ginkgo Bioworks (US),
Integrated DNA Technologies (US), New England Biolabs (US), Synthetic Genomics
(US), and Twist Bioscience (US).
To know about the
assumptions considered for the study, download the
pdf brochure
Major Market
Developments:
In 2017, Thermo Fisher (US) collaborated with AstraZeneca
(US) and offered its CRISPR technology to AstraZeneca’s entire drug discovery
platform. In 2017, Ginkgo Bioworks (US)
acquired Gen9 (US), a Cambridge based gene synthesis company. In 2017, Intrexon (US) collaborated with
Johnson Matthey (UK) to develop microbial strains for fermentative production
of peptide-based active pharmaceutical ingredients (APIs)
To speak to our
analyst for a discussion on the above findings, click
Speak to Analyst
No comments:
Post a Comment